Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elisidepsin
- Development stage
- Phase 1
- Lead developer
- PharmaMar
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Elisidepsin (PM02734) is a synthetic cyclic depsipeptide of the kahalalide family derived from a marine metabolite originally isolated from the sea slug Elysia rufescens. It exhibits broad-spectrum antineoplastic activity against various tumor types including breast, colon, pancreas, lung, and prostate cancers. The drug induces cell death primarily through mechanisms involving autophagy rather than classical apoptosis. Specifically, it impairs autophagic flux and inhibits the Akt/mTOR signaling pathway while activating death-associated protein kinase (DAPK). Elisidepsin has been evaluated in phase I and II clinical trials for advanced solid tumors and non-small-cell lung cancer[2][4][8][10].
- Brand names
- Irvalec
- Other names
- elisidepsinPM02734PM-02734PM 02734Irvalec
02
Targets
Sphingolipid (Sphingolipid metabolism)AKT (RAC-alpha serine/threonine-protein kinase)DAPK (Death-associated protein kinase family)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on elisidepsin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elisidepsin.